Literature DB >> 3598886

Ocular bioavailability and tissue distribution of [14C]ketorolac tromethamine in rabbits.

T L Ling, D L Combs.   

Abstract

The ocular bioavailability of 0.5% [14C]ketorolac tromethamine administered topically (50 microL) to the eye was determined. The ocular bioavailability of ketorolac was 4% in anesthetized rabbits and was determined by comparing drug concentrations in the aqueous humor after topical application with those obtained after intracameral injection of an equivalent dose of 0.25 mg of ketorolac tromethamine per eye. Although ketorolac administered to the eye was completely absorbed systemically, concentrations of ketorolac (AUC) were, on the average, 13 times higher in the aqueous humor than in plasma after topical administration. In a separate ocular distribution study, peak concentrations of radioactivity were achieved in the ocular tissues and in plasma within 1 h post instillation. Concentrations of total radioactivity were highest in the cornea and sclera and lowest in the lens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3598886     DOI: 10.1002/jps.2600760405

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

1.  In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note.

Authors:  Manjusha Malhotra; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2005-10-24       Impact factor: 3.246

Review 2.  The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology.

Authors:  P Koay
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

Review 3.  Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review.

Authors:  Bruce I Gaynes; Richard Fiscella
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  M M Buckley; R N Brogden
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

5.  Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas.

Authors:  Pravin Kondiba Pawar; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006-02-10       Impact factor: 3.246

6.  Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension.

Authors:  Bruce I Gaynes; Anne Onyekwuluje
Journal:  Clin Ophthalmol       Date:  2008-06

7.  A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery.

Authors:  Helga P Sandoval; Luis E Fernández de Castro; David T Vroman; Kerry D Solomon
Journal:  Clin Ophthalmol       Date:  2007-12

8.  Ocular pharmacokinetics of 0.45% ketorolac tromethamine.

Authors:  Mayssa Attar; Rhett Schiffman; Lisa Borbridge; Quinn Farnes; Devin Welty
Journal:  Clin Ophthalmol       Date:  2010-12-01

9.  Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac.

Authors:  M A Kapin; J M Yanni; M T Brady; T J McDonough; J G Flanagan; M H Rawji; D C Dahlin; M E Sanders; D A Gamache
Journal:  Inflammation       Date:  2003-10       Impact factor: 4.092

Review 10.  Clinical pharmacokinetics of ketorolac tromethamine.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.